NEW YORK (GenomeWeb News) – Oxford Gene Technology said today it signed a license agreement with the Cancer Cytogenomics Microarray Consortium to create a whole genome, cancer-specific microarray.

The technology will incorporate probes for more than 500 cancer genes and 130 cancer-associated genomic regions from CCMC's design for hematological and solid tumors, OGT said. By accurately identifying DNA copy number changes and the loss of heterozygosity associated with different cancer types, OGT hopes to improve cancer research through the agreement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.